📣 VC round data is live. Check it out!

Enovis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Enovis and similar public comparables like PROCEPT BioRobotics, Nakanishi, SonoScape, Vitrolife and more.

Enovis Overview

About Enovis

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.


Founded

1998

HQ

United States

Employees

7.4K

Website

enovis.com

Financials (LTM)

Revenue: $2B
EBITDA: $413M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Enovis Financials

Enovis reported last 12-month revenue of $2B and EBITDA of $413M.

In the same LTM period, Enovis generated $1B in gross profit, $413M in EBITDA, and $199M in net income.

Revenue (LTM)


Enovis P&L

In the most recent fiscal year, Enovis reported revenue of $2B and EBITDA of $403M.

Enovis is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 18%, and net margin of 8%.

See analyst estimates for Enovis
LTMLast FY202320242025202620272028
Revenue$2B$2B$2B$2B$2B
Gross Profit$1B$1B$991M$1B$1B
Gross Margin61%60%58%56%60%
EBITDA$413M$403M$170M($481M)($830M)
EBITDA Margin18%18%10%(23%)(37%)
EBIT Margin13%13%(3%)(5%)(1%)
Net Profit$199M$190M($33M)($825M)($1B)
Net Margin9%8%(2%)(39%)(53%)
Net Debt$1B

Financial data powered by Morningstar, Inc.

Enovis Stock Performance

Enovis has current market cap of $2B, and enterprise value of $3B.

Market Cap Evolution


Enovis' stock price is $26.12.

Enovis share price increased by 11.4% in the last 30 days, and decreased by 16.5% in the last year.

Enovis has an EPS (earnings per share) of $3.31.

See more trading valuation data for Enovis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$2B1.6%11.4%2.6%-16.5%$3.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Enovis Valuation Multiples

Enovis trades at 1.3x EV/Revenue multiple, and 7.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Enovis

EV / Revenue (LTM)


Enovis Financial Valuation Multiples

As of May 15, 2026, Enovis has market cap of $2B and EV of $3B.

Enovis has a P/E ratio of 7.6x.

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.3x1.7x1.4x1.3x
EV/EBITDA7.0x7.1x17.0x(6.0x)(3.5x)
EV/EBIT9.8x10.1x(59.6x)(27.9x)(152.7x)
EV/Gross Profit2.1x2.1x2.9x2.4x2.1x
P/E7.6x7.9x(45.2x)(1.8x)(1.3x)
EV/FCF74.6x126.4x225.7x(42.9x)144.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Enovis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Enovis Margins & Growth Rates

Enovis grew revenue by 4% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Enovis reported gross margin of 60%, EBITDA margin of 18%, and net margin of 8%.

See estimated margins and future growth rates for Enovis

Enovis Margins

Last FY202420252026202720282029
Gross Margin60%56%60%62%
EBITDA Margin18%(23%)(37%)18%
EBIT Margin13%(5%)(1%)13%
Net Margin8%(39%)(53%)9%
FCF Margin1%(3%)1%3%

Enovis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%23%7%4%
Gross Profit Growth7%19%14%7%
EBITDA Growth7%(383%)73%(152%)
EBIT Growth8%114%(82%)(1725%)
Net Profit Growth12%2382%43%(118%)
FCF Growth188%(627%)(130%)230%

Data powered by FactSet, Inc. and Morningstar, Inc.

Enovis Operational KPIs

Enovis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Enovis' Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Enovis' Rule of X is 29% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Enovis
LTMLast FY202320242025202620272028
Rule of 4023%23%
Bessemer Rule of X30%29%
Revenue per Employee$0.3M
Opex per Employee$0.2M
R&D Expenses to Revenue5%5%4%4%5%
Opex to Revenue61%61%61%61%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Enovis Competitors

Enovis competitors include PROCEPT BioRobotics, Nakanishi, SonoScape, Vitrolife, Immunocore Holdings, AdaptHealth, Nolato, Nihon Kohden, Haier Biomedical and Savaria.

Most Enovis public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
PROCEPT BioRobotics4.3x3.9x(26.6x)(32.6x)
Nakanishi2.4x2.3x9.9x9.6x
SonoScape3.9x3.7x33.1x31.2x
Vitrolife4.1x4.2x14.4x14.1x
Immunocore Holdings2.6x2.5x(287.3x)(42.0x)
AdaptHealth1.1x1.0x5.5x5.3x
Nolato1.5x1.5x8.8x8.8x
Nihon Kohden0.9x0.9x8.1x8.2x

This data is available for Pro users. Sign up to see all Enovis competitors and their valuation data.

Start Free Trial

Enovis M&A Activity

Enovis has acquired 2 companies to date.

Last acquisition by Enovis was on September 25th 2023. Enovis acquired Lima Corporate for $850M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Enovis

Lima Corporate
Insight Medical
Description
Lima Corporate is an Udine-headquartered Italian firm manufacturing orthopedic implants and traumatology devices. Surgeons rely on its Trabecular Titanium prostheses for hip, knee, shoulder, and revision arthroplasties plus small joint solutions. Custom 3D-printed components enable patient-specific reconstruction in complex cases. Founded in 1969, Lima Corporate exports to over 40 countries and collaborates with hospitals on additive manufacturing for personalized hardware in Europe and North America.
Insight Medical is a medical device developer specializing in orthopedic surgery tools. Its Augmented Reality Visualization and Information System supports joint replacement, ACL reconstruction, and spinal fusion with real-time tracking and preoperative planning displays. Laguna Hills, California-based since 2016, the company improves surgical precision through patient-specific visualizations.
HQ CountryUnited StatesUnited States
HQ City
Washington, DC
Los Angeles, CA
Deal Date25 Sep 20236 Jul 2022
Valuation$850M$73M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Enovis acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Enovis

When was Enovis founded?Enovis was founded in 1998.
Where is Enovis headquartered?Enovis is headquartered in United States.
How many employees does Enovis have?As of today, Enovis has over 7K employees.
Who is the CEO of Enovis?Enovis' CEO is Damien McDonald.
Is Enovis publicly listed?Yes, Enovis is a public company listed on NYSE.
What is the stock symbol of Enovis?Enovis trades under ENOV ticker.
When did Enovis go public?Enovis went public in 2008.
Who are competitors of Enovis?Enovis main competitors include PROCEPT BioRobotics, Nakanishi, SonoScape, Vitrolife, Immunocore Holdings, AdaptHealth, Nolato, Nihon Kohden, Haier Biomedical, Savaria.
What is the current market cap of Enovis?Enovis' current market cap is $2B.
What is the current revenue of Enovis?Enovis' last 12 months revenue is $2B.
What is the current revenue growth of Enovis?Enovis revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Enovis?Current revenue multiple of Enovis is 1.3x.
Is Enovis profitable?Yes, Enovis is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Enovis?Enovis' last 12 months EBITDA is $413M.
What is Enovis' EBITDA margin?Enovis' last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Enovis?Current EBITDA multiple of Enovis is 7.0x.
What is the current FCF of Enovis?Enovis' last 12 months FCF is $39M.
What is Enovis' FCF margin?Enovis' last 12 months FCF margin is 2%.
What is the current EV/FCF multiple of Enovis?Current FCF multiple of Enovis is 74.6x.
How many companies Enovis has acquired to date?As of May 2026, Enovis has acquired 2 companies.
What was the largest acquisition by Enovis?$850M acquisition of Lima Corporate on 25th September 2023 was the largest M&A Enovis has done to date.
What companies Enovis acquired?Enovis acquired Lima Corporate and Insight Medical.
In how many companies Enovis has invested to date?Enovis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Enovis

Lists including Enovis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial